San Fran­cis­co-area biotech gets new cash to launch clin­i­cal pro­gram for con­gen­i­tal sug­ar pro­cess­ing dis­ease

A rare dis­ease biotech from the sub­urbs of San Fran­cis­co has re­turned to the ven­ture well for a Se­ries B ex­ten­sion, aim­ing to get its lead pro­gram through its first clin­i­cal tri­als.

Gly­comine pulled in a new $35 mil­lion haul for the stud­ies, the biotech an­nounced Wednes­day morn­ing, and plans to launch a Phase I study for the lead com­pound by the end of the year. Wednes­day’s funds pushed Gly­comine’s Se­ries B to­tal to $68 mil­lion af­ter an ear­li­er raise back in Au­gust 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER